What PIAM does

PIAM Farmaceutici S.p.A. is an Italian specialty pharmaceutical company founded in 1915 and headquartered in Genoa. It develops, manufactures, and commercializes therapeutic products across three pillars: prescription pharmaceuticals and OTC/nutraceuticals (Pharma & OTX/Nutraceutici), orphan drugs for rare diseases (Farmaci per malattie rare), and foods for special medical purposes (Alimenti a fini medici speciali, branded MEDIFOOD), with a long-standing focus on phenylketonuria (PKU) management. Its most differentiated technology is a slow-release protein-substitute platform, introduced in 2002, used in medical foods for PKU patients, complemented by orphan drug assets such as Miglustat Dipharma (launched May 2020) for Niemann-Pick disease type C and Gaucher disease type 1.

The company runs a hybrid go-to-market model: a sales force targeting healthcare professionals and pharmacies in Italy for prescription and OTC products, and a direct-to-patient and patient-association model for medical foods and rare-disease therapies, where treatment centers and patient communities are central to access. Following its 2019 acquisition by French specialty materials group Arkema, PIAM established PIAM Iberia in Madrid in 2019, giving it a direct Spanish commercial presence alongside its Italian core. Headcount is reported at 101-250 employees, and the most recent disclosed revenue is €31.643M in 2018, implying a 7.77% CAGR over 2012-2018. Strategic priorities signaled by recent activity include expanding the rare-disease portfolio, deepening patient-community engagement, and replicating the Italian specialty model in adjacent European markets.

The business model is B2B/B2B2C: revenue is generated through pharmacy-channel distribution of prescription and OTC products in Italy and Spain, and through specialty medical-food and orphan-drug channels where reimbursement is typically provided by national health systems. Pricing is set within regulated reimbursement frameworks for rare diseases and competitive pharmacy-channel dynamics for OTC/nutraceuticals. Customer segments are Italian NHS (payer), Spanish NHS (payer), specialist prescribers (gatekeepers), and PKU / rare-disease patient communities (end users).

Name

PIAM

Legal name

PIAM Farmaceutici S.P.A.

Website

https://piamfarmaceutici.com

Company type

Private

Founded year

1915

Operating status

Operating

Headcount range

101–250 employees

Short description

PIAM Farmaceutici S.p.A. is an Italian specialty pharmaceutical company founded in 1915, developing prescription drugs, orphan drugs for rare diseases, and medical foods — particularly for PKU patients — with operations in Italy and Spain and a 2018 reported revenue of €31.643M.

Ownership category

akta.pro rank

Headquarters

HQ city

Genoa

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical products: PIAM generates revenue through the sale of pharmaceutical products including OTX (over-the-counter) medicines, nutraceuticals, rare disease medications, and special medical foods under the MEDIFOOD brand.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

PIAM Farmaceutici researches, develops, manufactures, and distributes pharmaceutical products organized in three product areas: Pharma & OTX/Nutraceuticals (prescription, OTC, and nutraceutical products across neurogeriatrics, cardiometabolism, respiratory, aesthetic/vascular medicine, and cellular oxidation), rare disease and low-prevalence pharmaceuticals (orphan drugs for inherited metabolic diseases, rare neurological conditions, and tuberculosis), and MEDIFOOD foods for special medical purposes (specialized nutrition for congenital protein and lipid metabolism disorders and pediatric specialty needs).

Product overview

PIAM Farmaceutici S.p.A. is an Italian pharmaceutical company founded in 1915 offering a diversified portfolio organized into three main product categories: (1) Pharma & OTX/Nutraceutici covering prescription medicines, over-the-counter products, and nutraceuticals across therapeutic areas including neurogeriatrics, cardiometabolism, respiratory, and vascular/aesthetic medicine; (2) Farmaci per malattie rare ed a bassa prevalenza comprising orphan drugs and treatments for rare diseases including inherited metabolic disorders and rare neurological conditions; and (3) Alimenti a fini medici speciali (MEDIFOOD) providing specialized nutritional products for dietary management of metabolic disorders, protein metabolism issues, and pediatric specialist nutrition. The company also offers slow-release protein substitutes developed in 2002 for PKU management and has recently launched Miglustat Dipharma for rare disease treatment in Italy. PIAM operates internationally through its PIAM Iberia subsidiary established in Madrid in 2019.

Differentiator

Problem solved

Functional benefit

Brands

• Medifood: Specialized nutritional line for medical food purposes, including dietary management of metabolic diseases
• Afenil

Products and services

• Pharma & OTX/Nutraceuticals Core pharmaceutical product line of PIAM comprising prescription medicines, over-the-counter (OTX) products, and nutraceuticals across the therapeutic areas of neurogeriatrics, cardiometabolism, respiratory, aesthetic/vascular medicine, and cellular oxidation. Sold through Italian pharmacies for use by physicians and patients across these conditions.
• Rare Disease and Low-Prevalence Pharmaceuticals PIAM's product line of pharmaceutical products for rare and low-prevalence diseases, including treatments for inherited metabolic diseases (such as PKU-related medications), rare neurological conditions, and tuberculosis. Includes generic versions of orphan drugs made available at affordable prices for the Italian healthcare system.
• MEDIFOOD - Foods for Special Medical Purposes MEDIFOOD is PIAM's specialized nutritional product line for dietary management of patients with conditions that make normal nutrition impossible or difficult. Products address congenital protein metabolism disorders, lipid metabolism disorders, fluid hypersecretion pathologies, low-protein dietary regimens, and specialized pediatric needs.
• Slow-Release Protein Substitutes PIAM's proprietary slow-release protein substitute products designed to mimic natural protein digestion in PKU (Phenylketonuria) patients. The formulations provide more stable amino acid absorption and reduce plasma phenylalanine fluctuations, supporting better dietary management of PKU and related congenital metabolic conditions.
• Miglustat Dipharma Miglustat Dipharma is an orphan drug for the treatment of rare diseases, launched in Italy by PIAM Farmaceutici in May 2020. It expanded PIAM's rare disease portfolio and supports the company's strategy of providing affordable generic-orphan treatments to the Italian healthcare system.

Quantifiable outcome

• CAGR 2012-2018 of 7.77%, demonstrating consistent growth

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• Bruschettini S.r.l.coreStrategic or Co-development Partner · 3 October 2024PIAM Farmaceutici and Bruschettini S.r.l. jointly offer scholarships for pharmacy students at the University of Genoa and co-sponsor charitable events including the International Shipping Pro Am supporting pediatric kidney disease research.
• Sezione Liguria della Società Chimica ItalianaminorStrategic or Co-development Partner · 3 October 2024Collaborates with PIAM Farmaceutici and Bruschettini to offer study scholarships for students at the University of Genoa in pharmaceutical chemistry programs.
• Fondazione Malattie Renali del BambinocoreStrategic or Co-development Partner · 18 June 2024PIAM Farmaceutici and Bruschettini jointly support the Fondazione Malattie Renali del Bambino, which operates for the benefit of the Giannina Gaslini Pediatric Hospital. The partnership involves sponsoring the International Shipping Pro Am golf event, with proceeds going to the foundation. The foundation promotes scientific research in pediatric kidney diseases.
• O.Ma.R – Osservatorio Malattie RareminorStrategic or Co-development PartnerPIAM collaborates with O.Ma.R (Osservatorio Malattie Rare) to produce patient testimonials and raise awareness about rare diseases such as Phenylketonuria (PKU).
• Fondo Malattie Renali del BambinocoreStrategic or Co-development PartnerLong-standing partnership supporting pediatric kidney disease research. PIAM and Bruschettini jointly support the organization benefiting the Giannina Gaslini Hospital.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Dipharma S.A. Italian/Swiss specialty pharma with focus on rare diseases and difficult-to-manufacture generics. Direct comparable given the Miglustat Dipharma partnership with PIAM and overlapping rare disease product portfolios.
• Chiesi Farmaceutici S.p.A. Italian privately-held pharmaceutical company focused on rare diseases, respiratory, and cardiometabolic therapeutic areas. Closely comparable therapeutic portfolio and Italian mid-cap pharma profile.
• Zambon S.p.A. Italian privately-held pharmaceutical company with respiratory, pain, and rare disease focus. Comparable in mid-cap Italian pharma profile and specialty therapeutic mix.
• Alfa Sigma S.p.A. Italian mid-sized pharma with focus on gastroenterology, cardiovascular, and rare diseases. Comparable Italian mid-cap specialty pharma with similar therapeutic breadth.
• Swedish Orphan Biovitrum (Sobi): European rare disease specialist with strong metabolic and PKU portfolio. Comparable in therapeutic focus on rare metabolic and inflammatory diseases, though substantially larger and listed.
• Recordati S.p.A. Italian specialty pharmaceutical company with a strong rare disease unit (Orphan Europe). Closely comparable to PIAM in heritage, geography, therapeutic breadth, and mid-cap positioning, with significantly larger scale.

Broad incumbents

• Menarini Group: Largest privately-held Italian pharmaceutical company with cardiometabolic, oncology, and consumer health portfolio. Broader Italian incumbent operating in overlapping therapeutic categories.
• BioMarin Pharmaceutical Inc. Global rare disease biopharma with a portfolio that directly overlaps PIAM's PKU franchise (Palynziq, Vimizim). Broader incumbent in the rare metabolic disease space PIAM addresses.
• Alexion / AstraZeneca Rare Disease: Global rare disease leader (acquired by AstraZeneca) operating across metabolic, neurologic, and hematologic rare conditions. Established large-scale incumbent in the same rare disease categories PIAM targets.
• Nutricia (Danone Specialty Nutrition): Global medical nutrition leader with substantial PKU and inherited metabolic disorder portfolio. Competes directly with PIAM's MEDIFOOD division in the special medical foods category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/piamfarmaceutici

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PIAM